507307677 05/27/2022

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7354599

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
BRIAN FURMANSKI	12/22/2021
NACHI GUPTA	01/11/2022
BRUCE SCHNEPP	01/04/2022
MICHELE STONE	12/16/2021

RECEIVING PARTY DATA

Name:	KRIYA THERAPEUTICS, INC.
Street Address:	1100 ISLAND DRIVE, STE. 203
City:	REDWOOD CITY
State/Country:	CALIFORNIA
Postal Code:	94065

PROPERTY NUMBERS Total: 2

Property Type	Number
Application Number:	17500898
PCT Number:	US2021054871

CORRESPONDENCE DATA

Fax Number: (202)371-2540

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2023712600

Email: kmurray@sternekessler.com, KSchroder@Sternekessler.com

Correspondent Name: STERNE, KESSLER, GOLDSTEIN AND FOX P.L.L.C.

Address Line 1: 1100 NEW YORK AVENUE NW Address Line 4: WASHINGTON, D.C. 20005

ATTORNEY DOCKET NUMBER:	4525.0320005
NAME OF SUBMITTER:	BONNIE NANNENGA-COMBS, REG NO. #67,836
SIGNATURE:	/Bonnie W. Nannenga-Combs/
DATE SIGNED:	05/27/2022

Total Attachments: 10

source=2022-05-25-Assignments-4525-0320005#page1.tif

source=2022-05-25-Assignments-4525-0320005#page2.tif
source=2022-05-25-Assignments-4525-0320005#page3.tif
source=2022-05-25-Assignments-4525-0320005#page4.tif
source=2022-05-25-Assignments-4525-0320005#page5.tif
source=2022-05-25-Assignments-4525-0320005#page6.tif
source=2022-05-25-Assignments-4525-0320005#page7.tif
source=2022-05-25-Assignments-4525-0320005#page8.tif
source=2022-05-25-Assignments-4525-0320005#page9.tif
source=2022-05-25-Assignments-4525-0320005#page10.tif

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned Inventors: Brian Furmanski, Nachi Gupta, Bruce Schnepp and Michele Stone hereby sell and assign to KRIYA THERAPEUTICS, INC., a corporation formed under the laws of California, whose mailing address is 1100 Island Drive, Suite 203, Redwood City, CA 94065 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

- (a) in the invention(s) known as VIRAL VECTOR CONSTRUCTS FOR DELIVERY OF NUCLEIC ACIDS ENCODING CYTOKINES AND USES THEREOF FOR TREATING CANCER for which application(s) for patent have been filed in the United States of America having a filing date of October 13, 2021 (also known as United States Application No. 17/500,898) and under the Patent Cooperation Treaty having an international filing date of October 13, 2021 (also known as International Application No. PCT/US2021/054871), in any and all applications thereon, in any and all Letters Patent(s) therefor, and
- (b) in any and all applications that claim the benefit of the patent application(s) listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and
- (c) in any and all inventions described in the patent applications listed above in part (a) or (b), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned Inventors had this assignment and sale not been made.

The undersigned Inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-

part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned Inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned Inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned Inventors hereby grant the patent practitioners associated with CUSTOMER NUMBER 26111 the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned Inventors hereby represent that he/she understands that the patent practitioners associated with CUSTOMER NUMBER 26111 are the legal representatives of, and attorneys for, the assignee, and are <u>NOT</u> the legal representatives of, and attorneys for, the Inventors.

•	executed by the undersigned Inventors on the date opposite
his/her name.	
Date: 12/22/2021	Signature of Inventor: / // // //
	Brian FURMANSKI
Date:	Signature of Inventor: //
	Nachi GUPTA
Date:	Signature of Inventor: //
	Bruce SCHNEPP
Date: 12 16 2021	Signature of Inventor: / Michele STONE
•	IVIICHEIE STONE

KRIYA THERAPEUTICS, INC.

By: /	
Name:	
Title:	
Date:	

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned Inventors: Brian Furmanski, Nachi Gupta, Bruce Schnepp and Michele Stone hereby sell and assign to KRIYA THERAPEUTICS, INC., a corporation formed under the laws of California, whose mailing address is 1100 Island Drive, Suite 203, Redwood City, CA 94065 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

- (a) in the invention(s) known as VIRAL VECTOR CONSTRUCTS FOR DELIVERY OF NUCLEIC ACIDS ENCODING CYTOKINES AND USES THEREOF FOR TREATING CANCER for which application(s) for patent have been filed in the United States of America having a filing date of October 13, 2021 (also known as United States Application No. 17/500,898) and under the Patent Cooperation Treaty having an international filing date of October 13, 2021 (also known as International Application No. PCT/US2021/054871), in any and all applications thereon, in any and all Letters Patent(s) therefor, and
- (b) in any and all applications that claim the benefit of the patent application(s) listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and
- (c) in any and all inventions described in the patent applications listed above in part (a) or (b), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor, and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned Inventors had this assignment and sale not been made.

The undersigned Inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-

part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned Inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned Inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned Inventors hereby grant the patent practitioners associated with CUSTOMER NUMBER 26111 the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned Inventors hereby represent that he/she understands that the patent practitioners associated with CUSTOMER NUMBER 26111 are the legal representatives of, and attorneys for, the assignee, and are <u>NOT</u> the legal representatives of, and attorneys for, the Inventors.

IN WITNESS WHEREOF, executed by the undersigned Inventors on the date opposite his/her name.

Date:		Signature of Inventor: /		1
		. ,	Brian FURMANSKI	
Date: Je-	1,2.22	Signature of Inventor: /_	Nachikuk Geytk.	
Date:		Signature of Inventor: /_	Bruce SCHNEPP	
Date:		Signature of Inventor: /	Michele STONE	

KRIYA THERAPEUTICS, INC.

By: /			. gt . 1 sayaya a		1

Name: _	 			 	
Title:	 				
Date:					

Page 3 of 3

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned Inventors: Brian Furmanski, Nachi Gupta, Bruce Schnepp and Michele Stone hereby sell and assign to KRIVA THERAPEUTICS, INC., a corporation formed under the laws of California, whose mailing address is 1100 Island Drive, Suite 203, Redwood City, CA 94065 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

- (a) in the invention(s) known as VIRAL VECTOR CONSTRUCTS FOR DELIVERY OF NUCLEIC ACIDS ENCODING CYTOKINES AND USES THEREOF FOR TREATING CANCER for which application(s) for patent have been filed in the United States of America having a filing date of October 13, 2021 (also known as United States Application No. 17/500,898) and under the Patent Cooperation Treaty having an international filing date of October 13, 2021 (also known as International Application No. PCT/US2021/054871), in any and all applications thereon, in any and all Letters Patent(s) therefor, and
- (b) in any and all applications that claim the benefit of the patent application(s) listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and
- (c) in any and all inventions described in the patent applications listed above in part (a) or (b), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned Inventors had this assignment and sale not been made.

The undersigned Inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-

part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned Inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned Inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned Inventors hereby grant the patent practitioners associated with CUSTOMER NUMBER 26111 the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned Inventors hereby represent that he/she understands that the patent practitioners associated with CUSTOMER NUMBER 26111 are the legal representatives of, and attorneys for, the assignee, and are <u>NOT</u> the legal representatives of, and attorneys for, the Inventors.

IN WITNESS WHEREOF, executed by the undersigned Inventors on the date opposite his/her name.

Date:	Signature of Inventor: /_	ì
	Brian FURMANSKI	
Date:	Signature of Inventor: /	/
Date: Jan 4, 2022	Nachi GUPTA Signature of Inventor: Bruce SCHNEPP	<u>)</u>
Date:	Signature of Inventor: /	1
	Michele STONE	

KRIYA THERAPEUTICS, INC.

By: /	
Name:	
Title:	
Date:	

Appl. Nos. 17/500,898 & PCT/US2021/054871 Atty. Docket Nos. 4525.0320005 & 4525.032PC04

KRIYA THERAPEUTICS, INC.

By: /2-0/10/2

Name: Watt Deltino

Title: Vice President of Intellectual Property

Date: 11-Jan - 2022_____